Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML
Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML
A recent clinical trial has unveiled a new prospect for treating relapsed/refractory acute myeloid leukemia (AML). The study delved into the safety and efficacy of a natural selection CD7 CAR-T cell (NS7 CAR-T cell) in treating CD7+ relapsed/refractory AML patients.
The research involved 10 cases of CD7+ relapsed/refractory AML, where 30% of AML patients expressed CD7. Following treatment with NS7 CAR-T cell infusion, the results showed that within 4 weeks post-infusion, 70% of patients achieved complete bone marrow remission (CR), with 6 patients achieving a deep remission at the level of minimal residual disease (MRD). Notably, the loss of CD7 was identified as a primary reason for non-response in some patients.
The study also indicated that the majority of patients (80%) experienced mild cytokine release syndrome (CRS) post-infusion, with no observed neurotoxicity.
Furthermore, for select patients, continuing with a second allogeneic hematopoietic stem cell transplantation post NS7 CAR-T cell treatment resulted in promising long-term outcomes. However, further exploration is required for patients who did not undergo consolidative transplants to enhance treatment efficacy.
Professor Lu Peihua(Lu Daopei Hospital) remarked that this study highlights the potential of CD7 CAR-T cells as a bridging therapy before transplantation, demonstrating preliminary therapeutic efficacy for relapsed/refractory AML patients. Nevertheless, a comprehensive evaluation of its efficacy requires a larger sample size and longer-term follow-up.
This preliminary study represents a significant advancement in the field of AML treatment, but collaborative efforts and more research are still necessary. Looking ahead, we anticipate further studies and treatment outcomes to bring more beneficial therapeutic options for the long-term survival of patients, supported by a broader patient cohort and collaborative efforts from the medical community.
The outlook for this CD7 CAR-T cell therapy is promising, especially for AML patients who have undergone various treatments and allogeneic hematopoietic stem cell transplants. We look forward to more in-depth research and treatment outcomes in the future, offering more beneficial treatment choices for long-term survival among patients.
(source: ClinicalTrials.gov registration number NCT04938115
Preliminary results published by Professor Lu Peihua and their team in a top-tier journal)
#AMLResearch #CancerTreatment #CARTTherapy #Leukemia #MedicalBreakthrough #Cancer #AML #Immunotherapy #ClinicalTrials #BloodCancer #PatientCare #HealthcareAdvances #PrecisionMedicine #ScienceAndHealth #MedicalScience #CancerSurvivor #AMLWarriors #ResearchProgress #CancerFree #HopeInTreatment #acutemyeloidleukemia
If a child unfortunately gets leukemia, should CAR-T Therapy be considered?
In recent years, CAR-T therapy has gained traction in treating leukemia. A quick search yields numerous articles, many of which describe the miraculous effects of CAR-T.
Is the efficacy of CAR-T therapy really that impressive? Should CAR-T therapy be considered for a child diagnosed with leukemia? Today, let’s unravel these doubts together!
What kind of leukemia patients can undergo CAR-T therapy?
Since most acute leukemia patients are sensitive to chemotherapy, chemotherapy is the preferred initial treatment. Currently, CAR-T therapy is primarily used for refractory and relapsed acute B-cell lymphoblastic leukemia patients.
For cases where 1-2 courses of chemotherapy fail to achieve complete remission (primary refractory), or relapse during chemotherapy, or experience ineffective re-treatment after relapse and re-chemotherapy (refractory relapse), CAR-T therapy is the preferred approach.
Celebrating a decade of being cancer-free for the world’s first leukemia child treated with CAR-T therapy
The world’s first leukemia child cured by CAR-T therapy celebrates 11 cancer-free years
On May 10th each year, Emily Whitehead commemorates the anniversary of her cancer-free survival. This year, she turns 18 and has officially become a nurse, leading a busy and joyful life. With the achievement of this significant milestone, the revolutionary cancer treatment known as CAR-T cell immunotherapy has been officially recognized! She has also become the spokesperson for this epic therapy.
Which CAR-T products are currently on the market?
Since 2017, the approval of the world’s first CAR-T products, Novartis’s Kymriah, and Kite Pharma’s Yescarta by the FDA, has heralded a new era in cell immunotherapy. Presently, there are 10 CAR-T drugs approved for market globally. Additionally, there are over 1,000 CAR-T clinical trials registered worldwide on Clinicaltrials, with nearly 500 projects in mainland China. The primary treatment areas include hematologic malignancies, along with solid tumors such as pancreatic cancer, liver cancer, lung cancer, breast cancer, and colorectal cancer.
More and more people are choosing to seek medical treatment in China. China’s technology in oncology, especially in CAR-T, is now on par with that of the United States. The fundamental reasons why many individuals with related diseases choose China are the high-quality services, pleasant environment, and comparatively affordable prices.
“If you’d like to inquire about the latest cancer-fighting technologies and treatments, you can contact us.”
whatsapp:+8613717959070